Alterations to the extracellular matrix have long been associated with cancer progression and therapeutic resistance. Schwörer et al. describe a mechanism whereby fibroblasts reroute metabolites to fuel the demands of collagen synthesis, leading to cancer progression.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rozario, T. & DeSimone, D. W. Dev. Biol. 341, 126–140 (2010).
Zhang, R. et al. BMC Cancer 18, 901 (2018).
Ignotz, R. A. & Massague, J. J. Biol. Chem. 261, 4337–4345 (1986).
Bernard, K. et al. J. Biol. Chem. 293, 1218–1228 (2018).
Hamanaka, R. B. et al. Am. J. Resp. Cell Mol. Biol. 61, 597–606 (2019).
Schwörer, S. et al. EMBO J. 39, e103334 (2020).
Voorde, J. V. et al. Sci. Adv. 5, eaau7314 (2019).
Schwörer, S. et al. Nat. Metab. https://doi.org/10.1038/s42255-021-00480-x (2021).
Kalluri, R. Nat. Rev. Cancer 16, 582–598 (2016).
Durning, P. & Schor, S. L. Lancet 324, 890–892 (1984).
Schor, S. L. et al. J. Cell Sci. 90, 391–399 (1988).
Zhu, J. et al. Science 372, 968–972 (2021).
Pavlova, N. N. et al. eLife 9, e62307 (2020).
Acknowledgements
Fig. 1 was generated using BioRender and adapted from “PDAC Histology”, by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W.K.R. declares research support from Incyte and support to an immediate family member as a founder, scientific advisory board member and stockholder of Sitryx Therapeutics; is a scientific advisory board member and stockholder of Caribou Biosciences; is a member of the scientific advisory board of Nirogy Therapeutics; and is a consultant for Merck, Pfizer, Mitobridge, Calithera Biosciences and Tempest Therapeutics. Z.A.B. declares no competing interests.
Rights and permissions
About this article
Cite this article
Bacigalupa, Z.A., Rathmell, W.K. Upcycling the TCA cycle—rewiring tumour-associated fibroblasts. Nat Metab 3, 1439–1440 (2021). https://doi.org/10.1038/s42255-021-00473-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s42255-021-00473-w